Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

By X. Montalban, Stephen L. Hauser, L. Kappos, Douglas L. Arnold, A. Bar-Or, G. Comi, J. de Seze, G. Giovannoni, H. Hartung, Bernhard Hemmer and 12 more. New England Journal of Medicine, 2017

1,605 citations recorded by the source corpus.

Subfields: Molecular Biology, Neurology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c261f4ef86ab4493c310e6ab400fb26adcb4acbf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Hans Lassmann

In Neurology

1. Hans Lassmann
2. G. Giovannoni
3. Ruth Dobson

In Pathology and Forensic Medicine

1. Hans Lassmann
2. G. Giovannoni
3. Ruth Dobson

Citations in the corpus

• Multiple sclerosis – a review (2018, background): “Recent positive trials of disease-modifying therapies in progressive MS offer those with more advanced MS the hope of slowing their disease progression, with preservation of residual function [8].”
• Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis (2019, background): “These inflammatory sites mainly contain CD8+ T-cells, a major component of CD20+ B-cells and a variable number of plasma cells and may in their most severe manifestations become organized in structures with features of tertiary lymph follicles (green dots).”